Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI North America CPhI North America
Not Confirmed
Not Confirmed
20-22 May, 2025
World Vaccine Conferen...World Vaccine Conference
Not Confirmed
Not Confirmed
22-24 April, 2025
Not Confirmed
Not Confirmed
22-25 April, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI North America CPhI North America
Industry Trade Show
Not Confirmed
20-22 May, 2025
World Vaccine Conferen...World Vaccine Conference
Industry Trade Show
Not Confirmed
22-24 April, 2025
Industry Trade Show
Not Confirmed
22-25 April, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/our-unmatched-efficiency-and-track-record-of-faster-dmf-filings-give-our-customers-a-critical-competitive-advantage
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/top-pharma-companies-drugs-in-2024-merck-s-keytruda-maintains-top-spot-as-novo-s-semaglutide-nips-at-its-heels
23 May 2023
// BUSINESSWIRE
Details:
VGA039 is a first-in-class antibody therapy that modulates Protein S, a key co-factor involved in thrombin generation during both initiation and propagation of coagulation, it had demonstrated efficacy in numerous congenital bleeding disorders, including VWD.
Lead Product(s): VGA039
Therapeutic Area: Genetic Disease Brand Name: VGA039
Study Phase: Phase IProduct Type: Antibody
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 04, 2023
Lead Product(s) : VGA039
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Vega Therapeutics Initiates Clinical Trial Program for VGA039, a First‑in‑Class Antibody Thera...
Details : VGA039 is a first-in-class antibody therapy that modulates Protein S, a key co-factor involved in thrombin generation during both initiation and propagation of coagulation, it had demonstrated efficacy in numerous congenital bleeding disorders, including...
Product Name : VGA039
Product Type : Antibody
Upfront Cash : Inapplicable
June 04, 2023
Details:
VGA039 is a first-in-class antibody therapy that modulates Protein S, a key co-factor involved in thrombin generation during both initiation and propagation of coagulation, it had demonstrated efficacy in numerous congenital bleeding disorders, including VWD.
Lead Product(s): VGA039
Therapeutic Area: Genetic Disease Brand Name: VGA039
Study Phase: Phase IProduct Type: Antibody
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 23, 2023
Lead Product(s) : VGA039
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : VGA039 is a first-in-class antibody therapy that modulates Protein S, a key co-factor involved in thrombin generation during both initiation and propagation of coagulation, it had demonstrated efficacy in numerous congenital bleeding disorders, including...
Product Name : VGA039
Product Type : Antibody
Upfront Cash : Inapplicable
May 23, 2023
ABOUT THIS PAGE